Testosterone therapy in patients with Duchenne muscular dystrophy and glucocorticoid-induced pubertal delay

Glucocorticoid therapy slows disease progression in Duchenne muscular dystrophy (DMD), but causes significant adverse effects, including delayed puberty or hypogonadism, obesity, insulin resistance and osteoporosis. Lack of puberty or hypogonadism further increases risk for osteoporosis and affects quality of life, but is not consistently addressed in DMD care. We sought to determine if testosterone therapy could induce puberty, and to examine the effects of testosterone therapy on body composition, bone health and metabolic indices, in glucocorticoid-treated patients with DMD.

Source: Neuromuscular Disorders - September 10, 2017 Category: Neurology Authors: C. Keefe, B. Wong, I. Rybalsky, K. Shellenbarger, C. Tian, J. Khoury, L. Hornung, M. Rutter Source Type: research